Cefazolin Sodium

This product is a first-generation cephalosporin for injection. It has a better antibacterial effect on positive cocci than the second and third generations. It ranks first among the first-generation cephalosporins in terms of its effect on negative bacilli, but is inferior to the second generation, let alone the third generation. This product is unstable to the beta-lactamase produced by negative bacilli, and some negative bacilli are already resistant. It has no antibacterial activity against Pseudomonas aeruginosa, Enterobacter and anaerobic Bacteroides fragilis. The antibacterial spectrum is similar to that of cephalexin, and it has antibacterial effects on Staphylococci (including enzyme-producing strains), Streptococci (except Enterococci), Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella, Haemophilus influenzae and Enterobacter aerogenes. The characteristics of this product are that it has a stronger effect on Gram-negative bacteria and weaker resistance to the beta-lactamase of Staphylococci.

Cefazolin Sodium This product is a sterile powder of cefazolin sodium. The content of cefazolin (C14H14N8O4S3) calculated as anhydrous should not be less than 86.0%; calculated as average filling volume, the content of cefazolin (C14H14N8O4S3) should be 95.0-105.0% of the labeled amount.

It is clinically used for infections of the respiratory tract, urogenital system, skin and soft tissue, bones and joints, bile duct, etc. caused by sensitive bacteria. It can also be used for endocarditis, sepsis, pharyngeal and ear infections.

The following reactions may occur: 1. Allergic reactions: rash, urticaria, increased eosinophilia, drug fever and other allergic reactions; 2. Renal toxicity: when using this product, you should be alert to the possibility of renal dysfunction; 3. Other reactions such as phlebitis, increased serum transaminase, positive Coomb's test, occasional hemolytic anemia, decreased neutrophils or platelets

Contraindicated in patients allergic to cephalosporin antibiotics

Note for children: Ceftriaxone should not be used to treat neonates and premature infants with hyperbilirubinemia

1. This product is incompatible with the following drugs and cannot be infused in the same bottle: amikacin sulfate, kanamycin sulfate, chlortetracycline hydrochloride, oxytetracycline hydrochloride, tetracycline hydrochloride, erythromycin gluconate, polymyxin B sulfate, colistin sodium methanesulfonate, pentobarbital, calcium gluconate, calcium gluconate. 2. This product can enhance the antibacterial effect in vitro when used in combination with gentamicin or amikacin. 3. This product may increase nephrotoxicity when used in combination with strong diuretics, and may increase the nephrotoxicity of the latter when used in combination with aminoglycoside antibiotics. 4. Probenecid can increase the blood concentration of this product and prolong its blood half-life.

Sealed storage

Harbin HEJIA Pharmaceutical Co., Ltd.

• Founded in:

  1995-05-26

• Address:

  Shangzhi Economic and Technological Development Zone

• Tax NO.:

  91230183744159225H

• Registered Funds:

  65.5 million yuan

• Email:

  Log in to view